Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen KYPROLIS (carfilzomib by Year
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide product sales ($M) ($M)
Amgen KYPROLIS (carfilzomib: $1,412M in FY2025, down 6.1% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,412 | -6.1% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 1,503 | +7.1% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 1,403 | +12.5% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 1,247 | +12.5% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 1,108 | +4.0% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 1,065 | +2.0% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 1,044 | +7.9% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 968 | +15.9% | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 835 | +20.7% | Form 10-K (filed 2018-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 692 | +35.2% | Form 10-K (filed 2018-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 512 | – | Form 10-K (filed 2018-02-13) ↗ |
Breakdown
What makes up KYPROLIS (carfilzomib
- KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — U.S. product sales ($M)913 · FY2025
- KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Rest of World (ROW) product sales ($M)499 · FY2025
- KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide reported sales growth YoY (%)-6.0% · FY2025
- KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%)12.0% · FY2023
Cite this data
StockData. (2026). Amgen KYPROLIS (carfilzomib ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-kyprolis-ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.